Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by LTOWNERon Mar 14, 2012 7:52am
231 Views
Post# 19666947

Ineficient Market/Liquidity

Ineficient Market/Liquidity

I can find no negatives for this company in the next 12 months, quite the opposite, and I have scoured the Sedar filings.

 

AM leased a facility in Ontario to produce wind turbine components for Vestas and Vestas is providing the funds to cover materials, as part of the contract.  The production began in January, so some of the start-up costs would have been incurred in Q4 2011, where AM reported the best earnings of the year and cash  of $14.8 on the balance sheet at year end.

 

We are weathering some relatively large selling of an illiquid stock, plus as they say "lower analyst coverage reduces visibility and makes the market less efficient."  This company really deserves some coverage.

 

If AM can get rid of the sellers, the stock should rise with the next quarterly report, announcement of the next dividend and probably the next special dividend. 

 

Last night another analyst on BNN, Barry Schwartz, sang the praises of the auto suppliers saying "auto parts makers will survive and thrive".  One of his top picks was Magna.

 

Do your own dd and beware of some of the scaremongers on StockHouse.  Too many times I have seen them do some damage, only to see a stock bounce back on its own merits.

Bullboard Posts